GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company with a robust pipeline of human vaccines and immunotherapies to address unmet medical needs in cancer and infectious disease. The Company’s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 70 granted or pending patent applications spread over 20 patent families.

GeoVax’s product pipeline includes ongoing human clinical trials in COVID-19,  and head and neck cancer. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors.  Read more about our product pipeline here and about our collaborations here.

Our products are based upon a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine.

The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.

The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. Read more about our technology here.